 | |
| Company type | Private |
|---|---|
| Industry | Pharmaceuticals |
| Founded | February 2015 |
| Founder | |
| Headquarters | New York City and Zug, Switzerland |
Key people | Justin Garrett[1] Chief Executive Officer |
| Products | Vecamyl, Daraprim |
| Website | www |
Vyera Pharmaceuticals (formerly Turing Pharmaceuticals) is a pharmaceutical company incorporated in Zug, Switzerland, with offices in New York City. The company started to do business in the US as Vyera Pharmaceuticals in September 2017.[2][3]
The company has two marketed products: Daraprim (pyrimethamine), for the treatment of toxoplasmosis, and Vecamyl (mecamylamine hydrochloride) for the treatment of hypertension. The company was widely criticized for raising the price of daraprim by 5456% following its acquisition of rights to the drug in 2015. The company's stock price dropped around 10% after the price increase of the drug.[4] CEO Martin Shkreli faced immense criticism for his actions.[5] The company was previously named after Alan Turing, the computer scientist.
On May 10, 2023, Vyera filed for Chapter 11 bankruptcy.[6]
- ^ "Leadership Team". Turing Pharmaceuticals. Retrieved 20 December 2016.
- ^ "Corporation Filings 08/27/2017 to 09/03/2017". Louisiana Secretary of State. Archived from the original on 15 January 2022. Retrieved 24 September 2017.
- ^ "Oxytocin intranasal - Vyera Pharmaceuticals". AdisInsight. Retrieved 24 September 2017.
- ^ Mullin, Emily (February 27, 2015). "Turing Pharma Says Daraprim Availability Will Be Unaffected By Shkreli Arrest". Forbes.com. Retrieved 2 February 2016.
- ^ Weintraub, Arlene (February 27, 2015). "Gadfly Pharma Investor Shkreli Starts Anew After Ousting From Retrophin". Forbes.com. Retrieved 19 December 2015.
- ^ "Convicted pharma fraudster Shkreli's companies file for bankruptcy". Wall Street Journal. May 10, 2023. Retrieved May 10, 2023.